Clifford A. Hudis, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses dose-dense chemotherapy for the treatment of patients with breast cancer.
Clinical Pearls
Clifford A. Hudis, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses dose-dense chemotherapy for the treatment of patients with breast cancer.
Early mathematical models suggested scheduling might be a viable alternative strategy to escalating the dose of conventional cytotoxic chemotherapies.
The big breakthrough in this area was the development of growth factors in the 1980s and 1990s.
This strategy represents a useful backbone for targeted therapies.
